PMID- 35942408
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220810
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the 
      First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial.
PG  - 8100323
LID - 10.1155/2022/8100323 [doi]
LID - 8100323
AB  - OBJECTIVE: To assess the clinical efficacy of programmed death 1 (PD-1) 
      inhibitors plus split-course radiotherapy in the first-line treatment of advanced 
      kidney cancer. METHODS: In this prospective, randomized, single-blinded, 
      controlled trial, 44 patients with advanced kidney cancer initially treated in 
      our hospital from January 2017 to December 2018 were recruited. They were 
      concurrently and randomly assigned at a ratio of 1 : 1 to the control group and 
      the study group, with 22 cases in each group. The control group received PD-1 
      inhibitor nivolumab combined with ipilimumab, and the study group received 
      split-course radiotherapy plus. The primary endpoint is clinical efficacy, and 
      the secondary endpoints are progression-free survival (PFS), overall survival 
      (OS), and adverse events (AEs). RESULTS: Nivolumab plus split-course radiotherapy 
      was associated with an objective remission rate (ORR) of 59.09% versus nivolumab 
      alone with an ORR of 27.27%. The median PFS was 21.5 months (95% CI: 14.1-NA) 
      after single nivolumab therapy and 28.1 months (95% CI: 24.5-NA) after nivolumab 
      plus split-course radiotherapy, with an HR of 1.875 (95% CI: 0.877-4.011). The 
      median OS was 27.1 months (95% CI: 20.7-NA) after single nivolumab therapy and 
      not reached after nivolumab plus split-course radiotherapy and an HR of 2.56 (95% 
      CI: 1.081-6.06). Nivolumab was associated with significantly better OS plus 
      split-course radiotherapy versus nivolumab alone. CONCLUSION: Nivolumab plus 
      split-course radiotherapy in patients with advanced renal cell carcinoma 
      significantly improves ORR and prolongs overall survival with a good safety 
      profile.
CI  - Copyright (c) 2022 Weiping Li et al.
FAU - Li, Weiping
AU  - Li W
AUID- ORCID: 0000-0002-6760-922X
AD  - Department of Urology, The First Hospital of Lanzhou University, Lanzhou 730030, 
      China.
FAU - Cao, Zhigang
AU  - Cao Z
AD  - Department of Urology, The 940 Hospital of Joint Logistics Support Force of 
      Chinese PLA, Lanzhou 730050, China.
FAU - Chang, Pengcheng
AU  - Chang P
AD  - Department of Urology, The First Hospital of Lanzhou University, Lanzhou 730030, 
      China.
FAU - Zhang, Bin
AU  - Zhang B
AUID- ORCID: 0000-0002-3743-4043
AD  - Department of Urology, The 940 Hospital of Joint Logistics Support Force of 
      Chinese PLA, Lanzhou 730050, China.
FAU - Li, Fudong
AU  - Li F
AD  - Department of Urology, The 940 Hospital of Joint Logistics Support Force of 
      Chinese PLA, Lanzhou 730050, China.
FAU - Chang, Dehui
AU  - Chang D
AD  - Department of Urology, The 940 Hospital of Joint Logistics Support Force of 
      Chinese PLA, Lanzhou 730050, China.
LA  - eng
PT  - Journal Article
DEP - 20220730
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9356868
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/08/10 06:00
MHDA- 2022/08/10 06:01
PMCR- 2022/07/30
CRDT- 2022/08/09 02:10
PHST- 2022/03/06 00:00 [received]
PHST- 2022/05/06 00:00 [revised]
PHST- 2022/05/16 00:00 [accepted]
PHST- 2022/08/09 02:10 [entrez]
PHST- 2022/08/10 06:00 [pubmed]
PHST- 2022/08/10 06:01 [medline]
PHST- 2022/07/30 00:00 [pmc-release]
AID - 10.1155/2022/8100323 [doi]
PST - epublish
SO  - J Oncol. 2022 Jul 30;2022:8100323. doi: 10.1155/2022/8100323. eCollection 2022.